Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05781152 · ClinicalTrials.gov registry record · Phase 4
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
A Phase 4 study of Crohn Disease, sponsored by Connecticut Children's Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT05781152 is a Phase 4 study of Crohn Disease that is actively recruiting participants, run by Connecticut Children's Medical Center. The registered enrollment target is 900 participants, above the 193-participant average among 71 other Crohn Disease trials with a reported enrollment target (366% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05781152, a Phase 4 study of Crohn Disease, is actively recruiting participants, sponsored by Connecticut Children's Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years w
Conditions Studied
Interventions
- DRUG Anti-TNF therapy
Study Locations (20)
California
- Cedars-Sinai - Los Angeles
- Rady Children's Hospital - San Diego and University of California, San Diego - San Diego
- UCSF Benioff Children's Hospitals - San Francisco
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- UH/Rainbow Babies and Children's Hospital - Cleveland
- Nationwide Children's Hospital - Columbus
New York
- Cohen Children's Medical Center of NY - Lake Success
- Columbia University Medical Center - New York
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Arizona
- Phoenix Children's Hospital - Phoenix
Connecticut
- Connecticut Children's Medical Center - Hartford
Georgia
- Emory University - Atlanta
Indiana
- Riley Hospital for Children at Indiana University Health - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2023-06-10 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05781152
The ClinicalTrials.gov registry entry for NCT05781152 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 193-participant average among 71 other Crohn Disease trials with a reported enrollment target (366% higher). The listed sponsor is Connecticut Children's Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which Anti-TNF therapy is the first listed.
NCT05781152 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, New York.
Frequently Asked Questions
What is clinical trial NCT05781152 about?
NCT05781152 is a clinical study titled "Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease". Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause o...
What is the current status of trial NCT05781152?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 900 participants. The study started on 2023-06-10. Estimated completion is 2029-07-01.
What conditions does trial NCT05781152 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT05781152?
The interventions under investigation include: Anti-TNF therapy (DRUG).
Who is sponsoring clinical trial NCT05781152?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05781152 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
-
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
RECRUITING · Phase 4
-
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
ACTIVE NOT RECRUITING · Phase 4
-
Triple Combination Therapy in High Risk Crohn's Disease (CD)
COMPLETED · Phase 4
-
Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
COMPLETED · Phase 4
-
Flagyl Microbiome in Crohn's Disease
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.